Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04302116

Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm

Infantile spasms (IS) are seizures associated with a severe infantile epileptic encephalopathy. Both cessation of spasms and electrographic response are necessary for the best neurodevelopmental outcomes. Adrenocorticotrophic hormone (ACTH), or prednisolone, or vigabatrin are considered the first-line treatment individually. However, ACTH expense and availability are the barriers in developing countries including Thailand. Vigabatrin, therefore, is the first recommended by Epilepsy Society of Thailand due to ACTH unavailability. Recently, combined steroid treatments (either ACTH or high dose prednisolone) with vigabatrin are superior in cessation of spasms compared to steroid treatment alone. Thus, this study is aimed to compare the efficacy of vigabatrin with high dose prednisolone combination therapy and vigabatrin alone.

Recruiting

Interested in participating?

Request Info

Key information

Age range

2 month–14 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Queen Sirikit National Institute of Child Health

Ratchathewi, Bangkok, 10400, Thailand

Location status: Recruiting

Location contact

Kantapon Trongkamolchai, MD

CONTACT

[email protected]

Kantapon Trongkamolchai, MD

SUB_INVESTIGATOR

Kullasate Sakpichaisakul, MD

CONTACT

[email protected]

Kullasate Sakpichaisakul, MD

PRINCIPAL_INVESTIGATOR

Ravindra Arya, MD, DM

SUB_INVESTIGATOR

Ravivan Wittawassamrankul, R Ph

SUB_INVESTIGATOR

Sirorat Suwannachote, MD

SUB_INVESTIGATOR

Somjit Sri-udomkajorn, MD

SUB_INVESTIGATOR

About this study

Infantile spasms are recognized as epileptic encephalopathy which include the hypsarrhythmia or variants electroencephalographic (EEG) features and psychomotor regression. Various underlying conditions are associated with the infantile spasm included cerebral malformation, hypoxic ischemic encephalopathy, genetic disorders (Down syndrome), tuberous sclerosis complex (TSC), etc. Although vigabatrin has the evidence to use as the first line treatment for infantile spasm related with TSC. Adrenocorticotrophic hormone (ACTH), or high dose prednisolone, or vigabatrin are the first line treatment of IS in non-TSC.

The effectiveness of ACTH versus high dose prednisolone question have not yet definitely answered. Furthermore, ACTH expense and availability are the barriers in developing countries including Thailand. Vigabatrin, therefore, is the first option of therapy recommended by Epilepsy Society of Thailand due to ACTH unavailability. Recently, combined steroid treatments (either ACTH or high dose prednisolone) with vigabatrin are superior in cessation of spasms compared to steroid treatment alone. Questions about the clinical cessation of IS and electrographic remission by combination treatment with vigabatrin and high dose prednisolone compare to vigabatrin alone have not fully elucidated. Thus, this study is aimed to compare the efficacy of vigabatrin with high dose prednisolone combination therapy and vigabatrin alone.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age at 2-14 months at date of enrollment
  • Clinical diagnosis of infantile spasm assessed by pediatric neurologist and hypsarrhythmic pattern or variants interpreted by pediatric epileptologist
  • Thai nationality

Exclusion criteria

  • Previous treatment (within the last 28 days) with vigabatrin or corticosteroid
  • Previous diagnosis of epileptic encephalopathy e.g. early infantile epileptic encephalopathy and early myoclonic epileptic encephalopathy
  • Has a clinical suspicious or diagnosis of tuberous sclerosis complex characterized by one of these; known affected parent, previously diagnosed cardiac rhabdomyoma, hypomelanotic macules, forehead fibrous plaque, shagreen patch, retinal phakoma, or known polycystic kidneys
  • A contraindication to vigabatrin or corticosteroid such as recent varicella or herpes zoster infection, gastrointestinal hemorrhage etc.
  • Thai language ability of the parents or guardians is that they may not understand what is being requested of them.
  • Predictable lack of availability of follow up

Treatment and study plan

Combination therapy with vigabatrin and prednisolone

Drug

High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months

Other names: Sabril with prednisolone

Vigabatrin Tablets

Drug

Vigabatrin (50-150 mg/kg/day) twice daily for 4 months

Other names: Sabril

Primary outcomes

  1. Cessation of spasms

    Time frame: Assessed during Day 14 to Day 42 after treatment.

    Defined as no witnessed spasms (either clusters or single spasms) from Day 14 to Day 42 inclusive.

Secondary outcomes

  1. Electrographic response

    Time frame: Assessed during Day 14 and Day 43 after treatment.

    Disappearance of hypsarrhythmia defined by Burden of Amplitudes and Epileptiform Discharges (BASED) scoring system < 2 at Day 14 and Day 43 after treatment.

  2. Electroclinical response

    Time frame: Between Day 14 and Day 21.

    the cessation of spasms with the addition of absence of hypsarrhythmia (BASED score < 2) on the Day 14 EEG. Valid Day 14 EEGs will be undertaken between Day 14 and Day 21 inclusive.

  3. Extended electroclinical response

    Time frame: Between Day 42 and Day 49.

    Electroclinical response with the addition of absence of hypsarrhythmia (BASED score < 2) on the Day 42 EEG. Valid Day 42 EEGs will be undertaken between Day 42 and Day 49 inclusive.

  4. The time taken to absence of spasms

    Time frame: Day 1 to Day 14

    Duration for clinical cessation of spasms after initiation treatment

  5. Relapse of spasms

    Time frame: Day 42 to 3 months after treatment

    Defined when a cluster of more than one spasm in reported after Day 42. No EEG is required.

  6. Adverse reactions

    Time frame: Day 1 to Day 14, from Day 15 to Day 42, and from Day 43 to 4 months into the trial

    Each adverse event will be evaluated by the principal investigator to determine whether in their view it is an adverse reaction. If considered an adverse reaction, it will be reported by using the standard classification.

  7. Epilepsy outcome at age 18 months

    Time frame: From Day 42 to age 18 months

    Epilepsy status and antiepileptic drugs (AEDs) will be recorded by using the following categories: 1) Infantile spasms (clusters of spasms), 2) Any other epileptic seizure including febrile seizures, and 3) Names of any preventive AEDs prescribed

Study contacts

Contact information is provided by the study sponsor or research team.

Kullasate Sakpichaisakul, MD

CONTACT

[email protected]

66-2-354-8333

Sirorat Suwannachote, MD

CONTACT

[email protected]

66-2-354-8333

Sponsors and collaborators

Lead sponsor

Kullasate Sakpichaisakul

Other Gov

Registry information

Official study title

Efficacy of Vigabatrin With High Dose Prednisolone Combination Therapy Versus Vigabatrin Alone for Infantile Spasm: a Randomized Trial

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Mar 10, 2020
Registry last updated
Aug 25, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.